At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
ALXN1210drug
Likely dose
ALXN1210 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Single Ascending and Multiple Set Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Healthy Japanese Subjects
In Brief
A Phase 1 clinical trial evaluating ALXN1210 for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams \[mg\]) of ALXN1210 following intravenous administration to healthy Japanese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartApr 2016
Primary CompletionJul 2017
First PostedMar 2022
TodayJul 2026
First PostedMar 21, 2022
Enrollment StartApr 18, 2016
Primary CompletionJul 5, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.3 years ago
Interventions
ALXN1210drug
Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.